Clinical Research Study| Volume 131, ISSUE 12, P1506-1514.e0, December 2018

Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism



      Few contemporary studies have assessed the management and outcomes of patients with massive and submassive pulmonary embolism. Given advances in therapy, we report contemporary practice patterns and event rates among these patients.


      We analyzed a prospective database of patients with massive and submassive pulmonary embolism. We report clinical characteristics, therapies, and outcomes stratified by pulmonary embolism type. Treatment escalation beyond systemic anticoagulation was defined as advanced therapy. Cox proportional hazards regression was used to identify predictors of 90-day mortality.


      Among 338 patients, 46 (13.6%) presented with massive and 292 (86.4%) with submassive pulmonary embolism. The average age was 63 ± 15 years, 49.9% were female, 32.0% had malignancy, and 21.9% had recent surgery. Massive pulmonary embolism patients received advanced therapy in 71.7% (30.4% systemic thrombolysis, 17.4% catheter-directed thrombolysis, 15.2% surgical embolectomy) and had greater 90-day mortality rates compared with submassive pulmonary embolism patients (41.3% vs 12.3%, respectively; P < .01). Most massive pulmonary embolism deaths (78.9%) occurred in-hospital, whereas mortality risk persisted after discharge for submassive pulmonary embolism. After multivariable adjustment, massive pulmonary embolism was associated with a 5.23-fold greater hazard of mortality (95% confidence interval, 2.70-10.13; P < .01). Advanced therapies among all pulmonary embolism patients were associated with a 61% reduction in mortality (95% confidence interval, 0.20-0.76; P < .01).


      Among contemporary massive and submassive pulmonary embolism patients, mortality remains substantial. Advanced therapies were frequently utilized and independently associated with lower mortality. Further investigation is needed to determine how to improve outcomes among these high-risk patients, including the optimal use of advanced therapies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heit JA
        The epidemiology of venous thromboembolism in the community.
        Arterioscler Thromb Vasc Biol. 2008; 28: 370-372
        • Anderson Jr, FA
        • Wheeler HB
        • Goldberg RJ
        • et al.
        A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.
        Arch Intern Med. 1991; 151: 933-938
        • Jaff MR
        • McMurtry MS
        • Archer SL
        • et al.
        Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 1788-1830
        • Konstantinides SV
        • Torbicki A
        • Agnelli G
        • et al.
        2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur Heart J. 2014; 35 (3069a-3069k): 3033-3069
        • Kearon C
        • Akl EA
        • Ornelas J
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Becattini C
        • Agnelli G
        Predictors of mortality from pulmonary embolism and their influence on clinical management.
        Thromb Haemost. 2008; 100: 747-751
        • Kucher N
        • Rossi E
        • De Rosa M
        • Goldhaber SZ
        Massive pulmonary embolism.
        Circulation. 2006; 113: 577-582
        • Weinberg I
        • Jaff MR
        Accelerated thrombolysis for pulmonary embolism: will clinical benefit be ULTIMAtely realized?.
        Circulation. 2014; 129: 420-421
        • Kabrhel C
        • Rosovsky R
        • Channick R
        • et al.
        A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism.
        Chest. 2016; 150: 384-393
        • Sista AK
        • Friedman OA
        • Dou E
        • et al.
        A pulmonary embolism response team's initial 20 month experience treating 87 patients with submassive and massive pulmonary embolism.
        Vasc Med. 2018; 23: 65-71
        • Provias T
        • Dudzinski DM
        • Jaff MR
        • et al.
        The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism.
        Hosp Pract (1995). 2014; 42: 31-37
        • Jain CC
        • Chang Y
        • Kabrhel C
        • et al.
        Impact of pulmonary arterial clot location on pulmonary embolism treatment and outcomes (90 days).
        Am J Cardiol. 2017; 119: 802-807
        • Goldhaber SZ
        Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy.
        J Thromb Haemost. 2009; 7(suppl 1): 322-327
        • Goldhaber SZ
        • Visani L
        • De Rosa M
        Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
        Lancet. 1999; 353: 1386-1389
        • Meyer G
        • Vicaut E
        • Danays T
        • et al.
        Fibrinolysis for patients with intermediate-risk pulmonary embolism.
        N Engl J Med. 2014; 370: 1402-1411
        • Cefalo P
        • Weinberg I
        • Hawkins BM
        • et al.
        A comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients <65 years.
        Am J Cardiol. 2015; 115: 681-686
        • Jimenez D
        • de Miguel-Diez J
        • Guijarro R
        • et al.
        Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry.
        J Am Coll Cardiol. 2016; 67: 162-170
        • Riera-Mestre A
        • Jimenez D
        • Muriel A
        • et al.
        Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism.
        J Thromb Haemost. 2012; 10: 751-759
        • Marti C
        • John G
        • Konstantinides S
        • et al.
        Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.
        Eur Heart J. 2015; 36: 605-614
        • Chatterjee S
        • Chakraborty A
        • Weinberg I
        • et al.
        Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.
        JAMA. 2014; 311: 2414-2421
        • Lin BW
        • Schreiber DH
        • Liu G
        • et al.
        Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry.
        Am J Emerg Med. 2012; 30: 1774-1781
        • Ibrahim SA
        • Stone RA
        • Obrosky DS
        • Geng M
        • Fine MJ
        • Aujesky D
        Thrombolytic therapy and mortality in patients with acute pulmonary embolism.
        Arch Intern Med. 2008; 168: 2183-2190
        • Jerjes-Sanchez C
        • Ramirez-Rivera A
        • de Lourdes Garcia M
        • et al.
        Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.
        J Thromb Thrombolysis. 1995; 2: 227-229

      Linked Article

      • Advanced Therapies for Massive Pulmonary Embolism
        The American Journal of MedicineVol. 131Issue 12
        • Preview
          The report by Secemsky et al1 in this issue of The American Journal of Medicine illustrates the current management of pulmonary embolism at the Massachusetts General Hospital (MGH). A Pulmonary Embolism Response Team sees all patients in whom pulmonary embolism is diagnosed by computed tomography. The team manages these patients during their hospitalization and after discharge for up to 1 year.1
        • Full-Text
        • PDF